Home

Aarti Drugs Ltd Quarterly Result

Image

Aarti Drugs Ltd

NSE: AARTIDRUGS

Net Profit - Last Quarter

₹ 34.96 Cr.

Last updated on: Jan 22, 2025

Aarti Drugs Ltd Quarterly Results Key Highlights

  • The revenue of Aarti Drugs Ltd for the Sep '24 is ₹ 599.81 crore as compare to the Jun '24 revenue of ₹ 556.45 crore.
  • This represent the growth of 7.79%a1# The ebitda of Aarti Drugs Ltd for the Sep '24 is ₹ 68.53 crore as compare to the Jun '24 ebitda of ₹ 66.07 crore.
  • This represent the growth of 3.72%a1# The net profit of Aarti Drugs Ltd for the Sep '24 is ₹ 34.96 crore as compare to the Jun '24 net profit of ₹ 33.27 crore.
  • This represent the growth of 5.08%a1#.

Aarti Drugs Ltd Quarterly Results Analysis

Market Price of Aarti Drugs Ltd

1M

1Y

3Y

5Y

Monitoring Aarti Drugs Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
22 Jan 2025415.9
21 Jan 2025425
20 Jan 2025425.85
17 Jan 2025421.25
16 Jan 2025421.3
15 Jan 2025415.25
14 Jan 2025420.15
13 Jan 2025422.65
10 Jan 2025429.95
09 Jan 2025442.35

Historical Revenue of Aarti Drugs Ltd

No data available

* All values are in crore

Historical EBITDA of Aarti Drugs Ltd

No data available

* All values are in crore

Historical Net Profit of Aarti Drugs Ltd

No data available

* All values are in crore

Aarti Drugs Ltd News Hub

Aarti Drugs hit 52-week high as board OKs Rs 60-cr share buyback

The buyback price fixed at Rs 900 per equity share, representing a 59.66% premium to Friday's closin

Read more

26 Aug 2024

Aarti Drugs to consider buyback

Aarti Drugs will hold a meeting of the Board of Directors of the Company on 26 August 2024. Powered

Read more

22 Aug 2024

Aarti Drugs soars on share buyback proposal

The announcement was made after market hours yesterday. Aarti Drugs forms part of $6 Billion Aarti G

Read more

22 Aug 2024

Board of Aarti Drugs approves buyback of shares up to Rs 59.85 cr

The Board of Aarti Drugs at its meeting held on 26 August 2024 has approved buyback of up to 6,65,00

Read more

26 Aug 2024

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for Quarterly Results of Aarti Drugs Ltd

What key financial metrics are included in Aarti Drugs Ltd's quarterly results?

Key financial metrics in Aarti Drugs Ltd's quarterly results typically include revenue, net profit, earnings per share (EPS), and operating margins. Other metrics might include cash flow, operating expenses, and client metrics.

When does Aarti Drugs Ltd announce its quarterly results?

Aarti Drugs Ltd usually announces its quarterly results around mid-July for Q1, mid-October for Q2, mid-January for Q3, and mid-April for Q4, aligning with the end of each fiscal quarter. However, different finance companies have their respective schedules for announcing their quarterly results.

How does Aarti Drugs Ltd's quarterly performance impact its stock price?

Aarti Drugs Ltd's quarterly performance can lead to stock price volatility, with strong results often driving the price up, while disappointing results can cause it to drop. Investor sentiment and market expectations also play significant roles.

What is the impact of Aarti Drugs Ltd's quarterly results on dividends?

The impact of Aarti Drugs Ltd's quarterly results on dividends can influence dividend decisions, with strong performance potentially leading to increased or special dividends, while weaker results might result in stable or reduced dividends.

Are there any special announcements usually made during Aarti Drugs Ltd's quarterly results?

Yes, Aarti Drugs Ltd often makes special announcements during its quarterly results, including strategic updates, key client wins, and major contract renewals. They might also guide future performance and share insights on industry trends. These updates are typically highlighted in their press release. However, special announcements made during quarterly results may vary from company to company.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions